Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Clinical trial NCT04201873 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04201873
- Sponsor
- Jonsson Comprehensive Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-08
- Primary completion
- 2025-07-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.